vimarsana.com

Pherecydes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AKKADIAN PARTNERS SECURES THE APPOINTMENT OF A LEGAL EXPERT - AND REQUESTS CALLS ON ERYTECH TO DEFER THE VOTE ON THE MERGER WITH PHERECYDES UNTIL AFTER THE LEGAL EXPERT S REPORT HAS BEEN SUBMITTED

Paris - June 15, 2023 - 7:30 am - In an Order dated June 14, 2023, the Summary Judgments Magistrate of the Commercial Court of Lyon ruled in favour of Akkadian Partners SA (hereafter "Akkadian") by

France generalJean lerouxAgence calyptusBruggeman mathieu calleuxSummary judgments magistrate of the commercial courtUltra high network investors uhnwisSummary judgments magistrateCommercial courtAkkadian partnersAbelia consultingGeneral meetingFamily officesUltra high network investors

Pherecydes Pharma: Commercial Court Rejects Akkadian s Request to Postpone the Merger Vote: Pherecydes and Erytech Shareholders Will Be Able to Vote on the Merger on June 23, 2023

Regulatory News: Pherecydes Pharma (FR0011651694 ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announced today

Dusan oresansky nicolas fossiezArthur rouillErytech pharmaPherecydes pharmaLyon commercial courtAkkadian pherecydes pharmaRegulatory newsLyon commercialAkkadian partnerOresansky nicolas fossiez

Erytech Pharma S A : ERYTECH announces that the Commercial Court has rejected Akkadian s request to postpone the vote on the merger with Pherecydes Pharma

ERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes Pharma Cambridge, MA (U.S.) and Lyon (France), June 14

United statesFrance generalUnited kingdomNicolas merigeauPherecydes pharmaEnregistrement universelPharma bioEric soyerMathilde bohin louis victor delouvrierExchange commissionCompany securitiesCompany annual report on formLyon commercial courtCommercial courtLyon commercialAkkadian partner

Akkadian Partners SA: Akkadian Suggests to Erytech an Alternative Strategy to its Merger with Pherecydes

Review of the true value of Erytech's assetsProposed strategy for ErytechAudit report requested by Akkadian stating the undervaluation of Erytechand the overvaluation of Phereceydes in the 1:1 parity adopted

France generalMecklenburg vorpommernUnited statesGil beyenSerono gensetEric soyerAgence calyptusBruggeman mathieu calleuxStefan klotterFrancis lefebvreNordic society of paediatric haematologyUltra high network investors uhnwisDrug administrationSecurity exchange commissionAkkadian partnersPharmium securities

Pherecydes Pharma: PHERECYDES Announces the Availability of the Exemption Document Relating to the Proposed Combination With Erytech Pharma

Regulatory News: PHERECYDES Pharma (FR0011651694 ALPHE), a biotechnology company specializing in extended phage therapy for treating antibiotic-resistant and/or complicated bacterial infections, announces

Gewinn nurArthur rouillPherecydes pharmaDusan oresansky nicolas fossiezRegulatory newsErytech pharmaGeneral meetingOresansky nicolas fossiez

vimarsana © 2020. All Rights Reserved.